Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Retrospective, Chart Review Study to Evaluate Ocular Disease Progression in Children With Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)

NCT04480476 is registered in ClinicalTrials.gov with REGENXBIO Inc. as lead sponsor.

NCT NCT04480476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Retrospective, Chart Review Study to Evaluate Ocular Disease Progression in Children With Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
Lead sponsor
REGENXBIO Inc.
Phase
Observational
Overall status
Withdrawn
Start date
March 31, 2021
Completion date
April 30, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

late-infantile neuronal ceroid lipofuscinosis type 2 (cln2)